Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC3971 | PF-431396 |
| Dual focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (PYK2) inhibitor (IC50 values are 2 and 11 nM respectively). Promotes osteoblast recruitment and activity, and stimulates bone formation in ovariectomized rats. | |
| BCC3981 | SW033291 |
| High affinity 15-hydroxyprostaglandin dehydrogenase (15-PGDH) inhibitor (Ki = 0.1 nM). Increases PGE2 levels in A549 cells in vitro, as well as in bone marrow, colon, lung and liver in mice. Promotes hematopoiesis, recovery from DSS-induced colitis, and hepatocyte proliferation after partial hepatectomy in mice. | |
| BCC3983 | SR-9243 |
| Selective LXR inverse agonist. Exhibits no significant activity at other nuclear receptors at maximally effective concentration. Inhibits the Warburg effect and lipogenesis by down-regulation of LXR-mediated gene expression. Selectively reduces cell viability and induces apoptosis in cancer cell lines in vitro. Suppresses hepatic steatosis and inhibits growth of tumor xenografts in mice. | |
| BCC4007 | Ro 3306 |
| ATP-competitive, potent cyclin-dependent kinase (cdk) 1 inhibitor (Ki values are 35 and 110 nM for cdk1/cyclin B1 and cdk1/cyclin A respectively). Induces G2/M phase cell cycle arrest and apoptosis. Downregulates the expression of antiapoptotic proteins such as Bcl-2 and survivin and enhances downstream p53 signaling in acute myeloid leukemia (AML). | |
| BCC4010 | HTH-01-015 |
| Potent and selective NUAK1 inhibitor (IC50 = 100 nM). Exhibits no significant inhibition against a panel of 139 kinases, including ten AMPK family members. Inhibits NUAK1-mediated MYPT1 phosphorylation. Also inhibits cell proliferation in U2OS cells in vitro, to a similar extent as NUAK1 knockdown models. | |
| BCC4014 | (+)-MK 801 Maleate |
| A potent, selective and non-competitive NMDA receptor antagonist. Acts by binding to a site located within the NMDA associated ion channel and thus prevents Ca2+ flux. An effective anti-ischemic agent in several animal models. Part of the Mixed NMDA Receptor. (-)-MK 801 maleate also available. | |
| BCC4022 | Ac-YVAD-AFC |
| Fluorogenic peptide substrate for caspase-1 (ICE). | |
| BCC4039 | XL413 hydrochloride |
| Potent and selective Cdc7 inhibitor (IC50 = 3.4 nM). Exhibits >12-fold selectivity for Cdc7 over PIM-1 kinase and >30-fold selectivity over pMCM and CK2. Inhibits proliferation of Colo 205 cells in vitro and attenuates tumor growth of Colo 205 xenografts in mice. | |
